Therapeutic vaccines for the treatment of severe atopic dermatitis and asthma
| Reference number | |
| Coordinator | Theravac Pharmacenticals AB |
| Funding from Vinnova | SEK 1 200 000 |
| Project duration | May 2012 - June 2014 |
| Status | Completed |
Purpose and goal
Our goal is to develop a vaccine against severe atopic dermatitis in dogs and also against asthma and dermatitis in humans. This is a product of a potential enormous market. The goal with the Vinnova project has been to establish a vaccine formulation that is safe and effective in dogs and to perform a small clinical trial in dogs with severe dermatitis to establish a Proof of Concept in a potential future patient population.
Results and expected effects
The project has been very successful and we have established a vaccine formulation that is effective, safe and easy to administrate. A number of tests in dogs have been needed to obtain these results which has resulted in that we have not yet performed the last step in the process to establish clinical proof of concept in patient dogs. However, this clinical study is planned and patient dogs are in the process of being recruited.
Approach and implementation
The Vinnova project has resulted in extremely valuable information concerning therapeutic vaccines in dogs and opened a potentially very large marked for such new products. There are now therapeutic vaccines in the pipeline for the treatment of many important diseases including allergy, other inflammatory diseases, and cancer, which can benefit from this new information. Theravac Ph AB has vaccine candidates for all these new areas of therapeutic vaccine development.